U01AG079847
Cooperative Agreement
Overview
Grant Description
Aim-AI: An actionable, integrated and multiscale genetic map of Alzheimer's disease via deep learning - project summary in response to PAR-19-269 "Cognitive systems analysis of Alzheimer's disease genetic and phenotypic data", in this proposal we assemble an interdisciplinary team to develop novel and robust analytical approaches to effectively address the current challenges in capitalizing on genetics, omics and neuroimaging data in Alzheimer's disease (AD).
Our team expertise covers complex disease genetics, functional genomics and regulation, machine learning/deep learning, systems-oriented research, neuroimaging, drug informatics, computational neuroscience, and clinical and translational science.
Artificial intelligence (AI) has been shown powerful in uncovering hidden features that are critical to disease diagnosis or etiology. However, merely making the AI models "explainable" does nothing for explainability of AD, including major effects detailed in molecular biology, pathology, and neuroimaging.
Our overall goal is to develop and implement a robust AI framework, namely AIM-AI, for transforming the genetic catalog of AD in a way that is actionable, integrated and multiscale, so that genetic factors have clear utility for subsequent etiological studies.
To make our findings actionable, we explore multiple-omics systems that functionally intercept the effects of genetic factors at the cell-type-specific and single-cell resolution. We will develop integrated and brain-data-driven collective systems, covering genetic, phenotypic, multi-omics, cell context, neuroimaging and knowledgebase information.
Finally, a multiscale systems biology approach will be implemented to identify genetic, neuroimaging, and phenotypic changes, which in combination can better explain the genetic architecture of AD and its cognitive decline. We will mine the AD characteristics at functional, cellular, tissue- and cell type-specific, and neuroimaging levels, enabling more rigorous assessment and validation that genetics effects indeed play out in cognitive decline and AD phenotypes.
Our proposal has three specific aims. Aim 1: Develop a deep learning framework, "DeepBrain-AD", to characterize the genetic risk of AD using both bulk brain tissue and single-cell regulatory genomics. Aim 2. Identify variants that account for cognitive decline due to AD progression by developing deep learning models that connect multiple modalities (imaging, clinical, genomics) in a joint analysis framework. Aim 3. Assess and validate the genetic variants from Aims 1 and 2 using multiple omics data to illustrate molecular systems which mediate their effects.
In summary, we will uniquely investigate and validate genetic variants and other markers in AD at multi-omics level, at the cell-type context and single-cell resolution; and link the genetic association signals with functional regulation, protein expression, and neuroimaging context; and finally explain their roles in cognitive decline due to AD progression.
The successful completion of this project will generate a robust AIM-AI framework, including machine learning methods/tools, resources, and scientific discoveries through integrative omics, deep learning, and other systems-based approaches, which will be immediately shared with AD and other disease research communities.
Our team expertise covers complex disease genetics, functional genomics and regulation, machine learning/deep learning, systems-oriented research, neuroimaging, drug informatics, computational neuroscience, and clinical and translational science.
Artificial intelligence (AI) has been shown powerful in uncovering hidden features that are critical to disease diagnosis or etiology. However, merely making the AI models "explainable" does nothing for explainability of AD, including major effects detailed in molecular biology, pathology, and neuroimaging.
Our overall goal is to develop and implement a robust AI framework, namely AIM-AI, for transforming the genetic catalog of AD in a way that is actionable, integrated and multiscale, so that genetic factors have clear utility for subsequent etiological studies.
To make our findings actionable, we explore multiple-omics systems that functionally intercept the effects of genetic factors at the cell-type-specific and single-cell resolution. We will develop integrated and brain-data-driven collective systems, covering genetic, phenotypic, multi-omics, cell context, neuroimaging and knowledgebase information.
Finally, a multiscale systems biology approach will be implemented to identify genetic, neuroimaging, and phenotypic changes, which in combination can better explain the genetic architecture of AD and its cognitive decline. We will mine the AD characteristics at functional, cellular, tissue- and cell type-specific, and neuroimaging levels, enabling more rigorous assessment and validation that genetics effects indeed play out in cognitive decline and AD phenotypes.
Our proposal has three specific aims. Aim 1: Develop a deep learning framework, "DeepBrain-AD", to characterize the genetic risk of AD using both bulk brain tissue and single-cell regulatory genomics. Aim 2. Identify variants that account for cognitive decline due to AD progression by developing deep learning models that connect multiple modalities (imaging, clinical, genomics) in a joint analysis framework. Aim 3. Assess and validate the genetic variants from Aims 1 and 2 using multiple omics data to illustrate molecular systems which mediate their effects.
In summary, we will uniquely investigate and validate genetic variants and other markers in AD at multi-omics level, at the cell-type context and single-cell resolution; and link the genetic association signals with functional regulation, protein expression, and neuroimaging context; and finally explain their roles in cognitive decline due to AD progression.
The successful completion of this project will generate a robust AIM-AI framework, including machine learning methods/tools, resources, and scientific discoveries through integrative omics, deep learning, and other systems-based approaches, which will be immediately shared with AD and other disease research communities.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Houston,
Texas
77030
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 200% from $1,278,119 to $3,829,167.
University Of Texas Health Science Center At Houston was awarded
AIM-AI: Genetic Map of Alzheimer's via Deep Learning
Cooperative Agreement U01AG079847
worth $3,829,167
from National Institute on Aging in September 2023 with work to be completed primarily in Houston Texas United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.866 Aging Research.
The Cooperative Agreement was awarded through grant opportunity Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
9/15/23
Start Date
8/31/28
End Date
Funding Split
$3.8M
Federal Obligation
$0.0
Non-Federal Obligation
$3.8M
Total Obligated
Activity Timeline
Transaction History
Modifications to U01AG079847
Additional Detail
Award ID FAIN
U01AG079847
SAI Number
U01AG079847-3593018781
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
ZUFBNVZ587D4
Awardee CAGE
0NUJ3
Performance District
TX-90
Senators
John Cornyn
Ted Cruz
Ted Cruz
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,278,119 | 100% |
Modified: 9/5/25